CIPLA

Cipla Ltd. shares jumped as much as 5% today after the pharmaceutical company announced it had received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paclitaxel, the generic version of Bristol Myers Squibb’s Abraxane